Reolysin: Completed Phase I enrollment

Oncolytics completed enrollment of 36 patients in the open-label, dose-escalation U.K. Phase I REO 012 trial evaluating IV Reolysin in combination with cyclophosphamide. Reolysin is also in Phase III ...